Connect with us


Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) Announces A New Business Logo and Website



Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) has announced a new website and logo. Additionally, the company has a new corporate presentation on its website.

Updates mark a shift from a preclinical to the clinical-stage company 

The updates align with its change from a pre-clinical to a clinical-stage corporation that focuses on complying with FDA regulations.

The new site has updated information on Cannabics’ drug candidates and their clinical path. It also offers the latest news for investors, such as SEC filings, press releases, and company presentations.

Cannabics is a company that deals with the discovery, development, and commercialization of cannabinoid medicines and technologies for the treatment of cancer. Its research and development facility is located in Israel. It has a license from the Ministry of Health that permits them to conduct clinical research on cannabinoids formulations for cancer.

The company, previously known as American Mining Corporation, has researched the effects of cannabinoid formulation on cancer tumors since it started in 2012. The company, which is a subsidiary of Cannabics Inc, changed its name in 2014. Cannabis uses advanced methodologies to determine the physiological effects different cannabinoids have in tumors.

Drugs cannabis is currently developing 

Recently, Cannabics has been focused on RCC-33, an oral capsule to treat colorectal cancer. RCC consists of a high concentration of cannabinoids such as cannabigerolic acid (CBGA) and cannabidivarin (CBDV).

Cannabics recently conducted a trial that infected mice with human colorectal cancer to test the drug’s efficacy. The results showed a survival rate of 31 days after the administration of RCC-33 compared to 23 days in mice in the control group. This was a 35% prolonged survival rate.

Cannabics Pharmaceuticals is planning a meeting with the U.S Food and Drug Administration (FDA) to discuss a pre-IND which will allow it to start Phase 1 and 2a trials by 2022.

It is also working on the development of Cannabics SR, an oral lipid capsule that consists of a standardized formulation of cannabinoids to treat cancer anorexia-cachexia syndrome. Another drug the company is working on is Cannabics CDx which gets drug sensitivity for cannabinoid cancer therapy.

The company has a goal to develop therapies that meet the particular need of individual cancer patients.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.


Business5 hours ago

CV Sciences Inc. (OTCMKTS: CVSI) Reports 8% Drop In Sales In Q3 2021 Attributable To Regulatory Uncertainty in CBD

Post Views: 7 CV Sciences Inc. (OTCMKTS: CVSI) has announced its third-quarter 2021 financial results for the period ending September...


AuxlyCannabis Group Inc. (OTCMKTS: CBWTF) Reports Net Revenue Growth 95% In Q3 2021

Post Views: 45 Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) has announced its financial results for the third quarter and nine...


Vivo Cannabis Inc. (OTCMKTS: VVCIF) Releases Q3 2021 Net Revenue of $6.2 Million as It Expands Internationally

Post Views: 31 Vivo Cannabis Inc. (OTCMKTS: VVCIF) has released its Q3 2021 operating and financial results for the quarter...

Business6 hours ago

Rubicon Organics Inc. (OTCMKTS: ROMJF) Announces 124% YoY Growth In Revenue in Q3 2021 After Launching New Brands

Post Views: 11 Rubicon Organics Inc. (OTCMKTS: ROMJF) has released its Q3 2021 results ending September 30, 2021, in which...

Business1 day ago

Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) Reports 120% Sequential Revenue Growth in Q3 2021

Post Views: 14 Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) has filed its unaudited consolidated preliminary financial statements for the quarter...

Business1 day ago

Indiva Limited (OTCMKTS: NDAF) Reports 143% YoY increase in Revenue In Q3 2021

Post Views: 46 Indiva Limited (OTCMKTS: NDAF) has announced its operating and financial results for the third quarter ending September...